Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.
By G. Appel, G. Contreras, M. Dooley, E. Ginzler, D. Isenberg, D. Jayne, Lei‐shi Li, E. Mysler, J. Sánchez-Guerrero, N. Solomons and 1 more. Journal of the American Society of Nephrology, 2009
1,008 citations recorded by the source corpus.
Subfields: Hepatology, Nephrology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/8c68417039192997b0404a92eef9f62d088ce2bc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
In Rheumatology
Citations in the corpus
- Systemic lupus erythematosus: Diagnosis and clinical management. (2019, background): “The larger ALMS lupus nephritis induction trial showed similar efficacy of mycophenolate compared to cyclophosphamide [191].”
- American College of Rheumatology Guidelines for Screening, Case Definition, Treatment and Management of Lupus Nephritis (2012, background): “The recommendation of initiating induction therapy with pulse glucocorticoids is based primarily on expert opinion; some recent prospective trials have employed pulse steroids at the onset of treatment (750 mg methylprednisolone daily 3 [41]), whereas others have not (27,29,30).”
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. (2012, result): “Interestingly, this finding parallels, to some extent, the observation that black patients had a better response to MMF than the response to intravenous cyclophosphamide observed in the ALMS trial (32,49).”
- KDIGO Clinical Practice Guideline for Glomerulonephritis (2012, background): “cyclophosphamide at 6 months, and had a similar incidence of adverse events including serious infections and deaths.(613) Enteric-coated mycophenolate sodium may also be effective in LN, as suggested by a small trial in cyclophosphamide resistant patients.”